Cargando…

Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy

On June 8, 2018, an NS3/4A protease inhibitor called danoprevir was approved in China to treat the infections of HCV genotype (GT) 1b – the most common HCV genotype worldwide. Based on phase 2 and 3 clinical trials, the 12-week regimen of ritonavir-boosted danoprevir (danoprevir/r) plus peginterfero...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miao, Miao, Jing, Xixi, De Clercq, Erik, Li, Guangdi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368560/ https://www.ncbi.nlm.nih.gov/pubmed/32764876 http://dx.doi.org/10.2147/DDDT.S254754

Ejemplares similares

Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
por: Rong, Libin, et al.
Publicado: (2013)

Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C
por: Wei, Lai, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China
por: Pan, Shufang, et al.
Publicado: (2021)

First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients
por: Chen, Hongyi, et al.
Publicado: (2020)

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
por: Cotter, Thomas G, et al.
Publicado: (2019)

Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective
por: Miao, Miao, et al.
Publicado: (2021)

Towards Efficient and Accurate SARS-CoV-2 Genome Sequence Typing Based on Supervised Learning Approaches
por: Miao, Miao, et al.
Publicado: (2022)

Antiviral Classification
por: Li, Guangdi, et al.
Publicado: (2021)

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
por: Ogawa, Eiichi, et al.
Publicado: (2017)

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
por: Miura, Itaru, et al.
Publicado: (2023)

Regulated Entry of Hepatitis C Virus into Hepatocytes
por: Miao, Zhijiang, et al.
Publicado: (2017)

Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy
por: Majeed, Chaudry Nasir, et al.
Publicado: (2022)

Endoplasmic Reticulum Stress in Hepatitis B Virus and Hepatitis C Virus Infection
por: Hu, Tengyue, et al.
Publicado: (2022)

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections(†)
por: De Clercq, Erik, et al.
Publicado: (2010)

Plitidepsin: design, development, and potential place in therapy
por: Alonso-Álvarez, Sara, et al.
Publicado: (2017)

Delafloxacin: design, development and potential place in therapy
por: Candel, Francisco Javier, et al.
Publicado: (2017)

Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf
por: De Clercq, Erik, et al.
Publicado: (2023)

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2017)

Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy
por: Phillips, Nancy A, et al.
Publicado: (2023)

Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection
por: Ke, Ruian, et al.
Publicado: (2015)

The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy
por: Yu, Miao
Publicado: (2020)

Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials
por: Casadei Gardini, Andrea, et al.
Publicado: (2019)

CT-P13: design, development, and place in therapy
por: Gabbani, Tommaso, et al.
Publicado: (2017)

Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
por: Deepak, Parakkal, et al.
Publicado: (2016)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
por: Pelaia, Corrado, et al.
Publicado: (2018)

Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy
por: Bowden, Sasigarn A, et al.
Publicado: (2018)

Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
por: Connett, GJ
Publicado: (2019)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
por: Bellesoeur, Audrey, et al.
Publicado: (2017)

Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
por: Soriano, Vicente, et al.
Publicado: (2023)

Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study
por: Li, Guangdi, et al.
Publicado: (2020)

Hepatitis C virus: Morphogenesis, infection and therapy
por: Morozov, Vladimir Alexei, et al.
Publicado: (2018)

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
por: Al-Sawaf, Othman, et al.
Publicado: (2017)

Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy
por: Romigi, Andrea, et al.
Publicado: (2018)

Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus
por: Grando, Aline Vitali, et al.
Publicado: (2017)

Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy
por: Davis, Elizabeth J, et al.
Publicado: (2017)

Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
por: Jenks, Jeffrey D, et al.
Publicado: (2018)

Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy
por: Sharma, Amol, et al.
Publicado: (2019)

Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy
por: Venur, Vyshak Alva, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2htdaj0q62lvmpkaj7sboirgki